Brief: Rezolute Announces Completion Of Enrollment In The Phase 3 Sunrize Study Of Ersodetug In Patients With Congenital Hyperinsulinism
28/05/2025 14:28
May 28 (Reuters) - Rezolute Inc RZLT.O: REZOLUTE ANNOUNCES COMPLETION OF ENROLLMENT IN THE PHASE 3 SUNRIZE STUDY OF ERSODETUG IN PATIENTS WITH CONGENITAL HYPERINSULINISM REZOLUTE INC - TOPLINE DATA ANTICIPATED IN DECEMBER 2025 REZOLUTE INC - ANTICIPATES BLA SUBMISSION FOR ERSODETUG IN 2026 Source text: ID:nGNX5yHBdh Further company coverage: RZLT.O ((Reuters.Briefs@thomsonreuters.com;))